microRNA-155 promotes the proliferation of prostate cancer cells by targeting annexin 7

被引:56
作者
Cai, Zhi-Kang [1 ]
Chen, Qi [1 ]
Chen, Yan-Bo [1 ]
Gu, Meng [1 ]
Zheng, Da-Chao [1 ]
Zhou, Juan [1 ]
Wang, Zhong [1 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Dept Urol & Androl, Shanghai 200011, Peoples R China
基金
中国国家自然科学基金;
关键词
prostate cancer; cell proliferation; miR-155; annexin; 7; CYCLE ARREST; LUNG-CANCER; EXPRESSION; APOPTOSIS; CARCINOMA; SURVIVAL; GENE;
D O I
10.3892/mmr.2014.2744
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Micro (mi)RNAs are a group of small non-coding RNA molecules that have been demonstrated to regulate the expression of genes involved in tumorigenesis. The relevance of microRNAs in the development, progression and prognosis of prostate cancer is not fully understood. miR-155 has been implicated in the induction of breast, lung and liver cancer, but its role in prostate cancer has not been investigated. In the present study, the biological function of miR-155 was investigated in prostate cancer for the first time, to the best of our knowledge. It was demonstrated that the expression of miR-155 was upregulated in prostate cancer tissues and cell lines as determined by quantitative reverse transcription-polymerase chain reaction. Furthermore, overexpression of miR-155 promoted cell proliferation, as indicated by MTT assay. Flow cytometric analysis demonstrated that inhibition of miR-155 induced cell cycle arrest and promoted apoptosis in prostate cancer cells. In addition, western blot analysis indicated that annexin (ANX)7 was significantly downregulated in prostate cancer tissues and cells. A luciferase reporter assay indicated that ANX7 was a target of miR-155, which suggested that miRNA-155 promoted the proliferation of prostate cancer cells by regulating ANX7 expression levels.
引用
收藏
页码:533 / 538
页数:6
相关论文
共 25 条
  • [1] Heterogeneity of gleason grade in multifocal adenocarcinorna of the prostate
    Arora, R
    Koch, MO
    Eble, JN
    Ulbright, TM
    Li, L
    Cheng, L
    [J]. CANCER, 2004, 100 (11) : 2362 - 2366
  • [2] Dunn Mary Weinstein, 2011, Semin Oncol Nurs, V27, P241, DOI 10.1016/j.soncn.2011.07.002
  • [3] Fang YX, 2013, ONCOGENE
  • [4] Screening for prostate cancer at low PSA range:: The impact of digital rectal examination on tumor incidence and tumor characteristics
    Gosselaar, Claartje
    Roobol, Monique J.
    Roemeling, Stijn
    van der Kwast, Theo H.
    Schroder, Fritz H.
    [J]. PROSTATE, 2007, 67 (02) : 154 - 161
  • [5] Clinical significance of CXCL16/CXCR6 expression in patients with prostate cancer
    Ha, Hong Koo
    Lee, Wan
    Park, Hyun Jun
    Lee, Sang Don
    Lee, Jeong Zoo
    Chung, Moon Kee
    [J]. MOLECULAR MEDICINE REPORTS, 2011, 4 (03) : 419 - 424
  • [6] Identification of microRNAs differentially expressed between lung squamous cell carcinoma and lung adenocarcinoma
    Hamamoto, Junko
    Soejima, Kenzo
    Yoda, Satoshi
    Naoki, Katsuhiko
    Nakayama, Sohei
    Satomi, Ryosuke
    Terai, Hideki
    Ikemura, Shinnosuke
    Sato, Takashi
    Yasuda, Hiroyuki
    Hayashi, Yuichiro
    Sakamoto, Michiie
    Takebayashi, Toru
    Betsuyaku, Tomoko
    [J]. MOLECULAR MEDICINE REPORTS, 2013, 8 (02) : 456 - 462
  • [7] Higgs Gadareth, 2013, J Clin Bioinforma, V3, P17, DOI 10.1186/2043-9113-3-17
  • [8] Huang X, 2013, CANC RES
  • [9] Construction of HCC-targeting artificial miRNAs using natural miRNA precursors
    Huang, Xiaoming
    Jia, Zhenyu
    [J]. EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2013, 6 (01) : 209 - 215
  • [10] microRNAs as tumor inhibitors, oncogenes, biomarkers for drug efficacy and outcome predictors in lung cancer
    Jiang, Yan-Wen
    Chen, Liang-An
    [J]. MOLECULAR MEDICINE REPORTS, 2012, 5 (04) : 890 - 894